Update on genetic and molecular markers associated with myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 50, Issue 3, 2009, Pages 341-348

  Valent, Peter ^a   Wieser, Rotraud ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Leukemia; MDS; Molecular markers; Point mutations; Prognosis

Indexed keywords

HFE PROTEIN; JANUS KINASE 2; K RAS PROTEIN; LENALIDOMIDE; MOLECULAR MARKER; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHROMOSOME ABERRATION; CHROMOSOME DELETION 5; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL CLASSIFICATION; DRUG TARGETING; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; HUMAN; MALIGNANT TRANSFORMATION; MARKER GENE; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOMATIC MUTATION; SURVIVAL TIME; THROMBOCYTOSIS;

CHROMOSOME ABERRATIONS; GENE EXPRESSION PROFILING; HUMANS; MYELODYSPLASTIC SYNDROMES; POINT MUTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 67650873364     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902756107     Document Type: Review

References (85)

1. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. Gralnick, H. R. et al. (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 51, pp. 189-199.
2. Brunning, R. D., Bennett, J. M., Flandrin, G., Matutes, E., Head, D. Vardiman, J. W. et al. (2001) Myelodysplastic syndromes. World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues, 1, pp. 62-73. IARC Press, Lyon
3. Fenaux, P. (2001) Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol, 73, pp. 429-437.
4. Hofmann, W. K. and Koeffler, H. P. (2005) Myelodysplastic syndrome. Annu Rev Med, 56, pp. 1-16.
5. Valent, P., Horny, H. P., Bennett, J. M., Fonatsch, C., Germing, U. Greenberg, P. et al. (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res, 31, pp. 727-736.
6. Nimer, S. D. (2008) Myelodysplastic syndromes. Blood, 111, pp. 4841-4851.
7. Aul, C., Gattermann, N., Heyll, A., Gerrming, U., Derigs, G. and Schneider, W. (1992) Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia, 6, pp. 52-59.
8. Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J. and Machin, D. (1985) Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol, 59, pp. 425-433.
9. Toyama, K., Ohyashiki, K., Yoshida, Y., Abe, T., Asano, S. Hirai, H. et al. (1993) Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: A multicentric study in Japan. Leukemia, 7, pp. 499-508.
10. Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P. Sanz, G. et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, pp. 2079-2088.
11. Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C. and Invernizzi, R. (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol, 25, pp. 3503-3510.
12. Mhawech, P. and Saleem, A. (2001) Myelodysplastic syndrome: Review of the cytogenetic and molecular data. Crit Rev Oncol Hematol, 40, pp. 229-238.
13. Haase, D., Germing, U., Schanz, J., Pfeilstocker, M., Nosslinger, T. Hildebrandt, B. et al. (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood, 110, pp. 4385-4395.
14. Schanz, J., Slovak, M. L., Ohyashiki, K., Sole, F., del Mar Mallo, M Steidl, C. et al. (2008) New prognostic data on rare cytogenetic abnormalities in MDS: A collaborative study of the international working group on MDS cytogenetics. Blood, 112, p. 2688.
15. Giagounidis, A. A., Germing, U. and Aul, C. (2006) Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res, 12, pp. 5-10.
16. List, A., Dewald, G., Bennett, J. M. Giagounidis, A. A. et al. (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med, 355, pp. 1456-1465.
17. Cutler, C. S., Lee, S. J., Greenberg, P., Deeg, H. J., Perez, W. S. Anasetti, C. et al. (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood, 104, pp. 579-585.
18. de Witte, T., Hermans, J., Vossen, J., Bacigalupo, A., Meloni, G. Jacobsen, N. et al. (2000) Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary leukemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol, 110, pp. 620-630.
19. Jaju, R. J., Boultwood, J., Oliver, F. J., Kostrzewa, M., Fidler, C. Parker, N. et al. (1998) Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer, 22, pp. 251-256.
20. Wlodarska, I., Selleri, L., La Starza, R., Paternotte, C., Evans, G. A. Boogaerts, M. et al. (1999) Molecular cytogenetics localizes two new breakpoints on 11q23.3 and 21q11.2 in myelodysplastic syndrome with t(11;21) translocation. Genes Chromosomes Cancer, 24, pp. 199-206.
21. Doöhner, K., Brown, J., Hehmann, U., Hetzel, C., Stewart, J. Lowther, G. et al. (1998) Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood, 92, pp. 4031-4035.
22. Bench, A. J., Nacheva, E. P., Hood, T. L., Holden, J. L., French, L. Swanton, S. et al. (2000) Chromosome 20 deletions in myeloid malignancies: Reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene, 19, pp. 3902-3913.
23. Mitani, K., Ogawa, S., Tanaka, T., Miyoshi, H., Kurokawa, M. Mano, H. et al. (1994) Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J, 13, pp. 504-510.
24. Nucifora, G., Begy, C. R., Kobayashi, H., Roulston, D., Claxton, D. Pedersen-Bjergaard, J. et al. (1994) Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci USA, 91, pp. 4004-4008.
25. Morishita, K., Parganas, E., William, C. L., Whittaker, M. H., Drabkin, H. Oval, J. et al. (1992) Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA, 89, pp. 3937-3941.
26. Suzukawa, K., Parganas, E., Gajjar, A., Abe, T., Takahashi, S. Tani, K. et al. (1994) Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood, 84, pp. 2681-2688.
27. Vinatzer, U., Mannhalter, C., Mitterbauer, M., Gruener, H., Greinix, H. Schmidt, H. H. et al. (2003) Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia. Genes Chromosomes Cancer, 36, pp. 80-89.
28. Soderholm, J., Kobayashi, H., Mathieu, C., Rowley, J. D. and Nucifora, G. (1997) The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia, 11, pp. 352-358.
29. Aytekin, M., Vinatzer, U., Musteanu, M., Raynaud, S. and Wieser, R. (2005) Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5'-ends. Gene, 356, pp. 160-168.
30. Wieser, R. (2007) The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene, 396, pp. 346-357.
31. Mitani, K. (2004) Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene, 23, pp. 4263-4269.
32. Nanjundan, M., Nakayama, Y., Cheng, K. W., Lahad, J., Liu, J. Lu, K. et al. (2007) Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res, 67, pp. 3074-3084.
33. Buonamici, S., Li, D., Chi, Y., Zhao, R., Wang, X. Brace, L. et al. (2004) EVI1 induces myelodysplastic syndrome in mice. J Clin Invest, 114, pp. 713-719.
34. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C. Harrison, G. et al. (1998) The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood, 92, pp. 2322-2333.
35. Yin, C. C., Cortes, J., Barkoh, B., Hayes, K., Kantarjian, H. and Jones, D. (2006) t(3;21)(q26;q22) in myeloid leukemia: An aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer, 106, pp. 1730-1738.
36. Reiter, E., Greinix, H., Rabitsch, W., Keil, F., Schwarzinger, I. Jaeger, U. et al. (2000) Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversioin inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26). Ann Hematol, 79, pp. 374-377.
37. Weisser, M., Haferlach, C., Haferlach, T. and Schnittger, S. (2007) Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3)(q21;q26) positive AML. Leuk Lymphoma, 48, pp. 2145-2151.
38. Sperr, W. and Valent, P. (2007) Biology and clinical features of myeloid neoplasms with inv(3)(q21q26) or t(3;3)(q21q26). Leuk Lymphoma, 48, pp. 2096-2097.
39. Haase, D. (2008) Cytogenetic features in myelodysplastic syndromes. Ann Hematol, 87, pp. 515-526.
40. Wlodarska, I., Mecucci, C., Marynen, P., Guo, C., Franckx, D. La Starza, R. et al. (1995) TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). Blood, 85, pp. 2848-2852.
41. Carroll, M., Tomasson, M. H., Barker, G. F., Golub, T. R. and Gilliland, D. G. (1996) The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA, 93, pp. 14845-14850.
42. Steer, E. J. and Cross, N. C. (2002) Myeloproliferative disorders with translocations of chromosome 5q31-35: Role of the platelet-derived growth factor receptor Beta. Acta Haematol, 107, pp. 113-122.
43. Apperley, J. F., Gardembas, M., Melo, J. V., Russell-Jones, R., Bain, B. J. Baxter, E. J. et al. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med, 347, pp. 481-487.
44. Boultwood, J., Fidler, C., Strickson, A. J., Watkins, F., Gama, S. Kearney, L. et al. (2002) Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood, 99, pp. 4638-4641.
45. Ebert, B. L., Pretz, J., Bosco, J., Chang, C. Y., Tamayo, P. Galili, N. et al. (2008) Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature, 451, pp. 335-339.
46. Pellagatti, A., Jadersten, M., Forsblom, A. M., Cattan, H., Christensson, B. Emanuelsson, E. K. et al. (2007) Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA, 104, pp. 11406-11411.
47. Hirai, H., Kobayashi, Y., Mano, H., Hagiwara, K., Maru, Y. Omine, M. et al. (1987) A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature, 327, pp. 430-432.
48. Liu, E., Hjelle, B., Morgan, R., Hecht, F. and Bishop, J. M. (1987) Mutations of the Kirsten-ras proto-oncogene in human preleukaemia. Nature, 330, pp. 186-188.
49. Harada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A. and Inaba, T. (2004) High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood, 103, pp. 2316-2324.
50. Nolte, F. and Hofmann, W. K. (2008) Myelodysplastic syndromes: Molecular pathogenesis and genomic changes. Ann Hematol, 87, pp. 777-795.
51. Watanabe-Okochi, N., Kitaura, J., Ono, R., Harada, H., Harada, Y. Komeno, Y. et al. (2008) AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood, 111, pp. 4297-4308.
52. Niimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J. Inaba, T. et al. (2006) Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia, 20, pp. 635-644.
53. Kurzrock, R., Albitar, M., Cortes, J. E., Estey, E. H., Faderl, S. H. Garcia-Manero, G. et al. (2004) Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol, 22, pp. 1287-1292.
54. Gore, S. D. (2005) Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol, 2, pp. S30-S35.
55. Steensma, D. P., Dewald, G. W., Lasho, T. L., Powell, H. L., McClure, R. F. Levine, R. L. et al. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syndromes. Blood, 106, pp. 1207-1209.
56. Ohyashiki, K., Aota, Y., Akahane, D., Gotoh, A., Miyazawa, K. Kimura, Y. et al. (2005) The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia, 19, pp. 2359-2360.
57. Ingram, W., Lea, N. C., Cervera, J., Germing, U., Fenaux, P. Cassinat, B. et al. (2006) The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia, 20, pp. 1319-1321.
58. Gattermann, N., Billiet, J., Kronenwett, R., Zipperer, E., Germing, U. Nollet, F. et al. (2007) High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count > 600 × 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood, 109, pp. 1334-1335.
59. Szpurka, H., Tiu, R., Murugesan, G., Aboudola, S., Hsi, E. D. Theil, K. S. et al. (2006) Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood, 108, pp. 2173-2181.
60. Fritsche-Polanz, R., Jordan, J. H., Feix, A., Sperr, W. R., Sunder-Plassmann, G. Valent, P. et al. (2001) Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol, 113, pp. 357-364.
61. Bernd, H. W., Sotlar, K., Lorenzen, J., Osieka, R., Fabry, U. Valent, P. et al. (2004) Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol, 57, pp. 324-328.
62. Valent, P., Akin, C., Sperr, W. R., Horny, H. P., Arock, M. Lechner, K. et al. (2003) Diagnosis and treatment of systemic mastocytosis: State of the art. Br J Haematol, 122, pp. 695-717.
63. Horny, H. P., Sotlar, K. and Valent, P. (2007) Mastocytosis: State of the art. Pathobiology, 74, pp. 121-132.
64. Mukhina, G. L., Buckley, J. T., Barber, J. P., Jones, R. J. and Brodsky, R. A. (2001) Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia. Br J Haematol, 115, pp. 476-482.
65. Steensma, D. P., Gibbons, R. J. and Higgs, D. R. (2005) Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood, 105, pp. 443-452.
66. Steensma, D. P., Higgs, D. R., Fisher, C. A. and Gibbons, R. J. (2004) Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood, 103, pp. 2019-2026.
67. Gattermann, N. (2000) From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk Res, 24, pp. 141-151.
68. Wulfert, M., Kupper, A. C., Tapprich, C., Bottomley, S. S., Bowen, D. Germing, U. et al. (2008) Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol, 36, pp. 577-586.
69. Shin, M. G., Kajigaya, S., Levin, B. C. and Young, N. S. (2003) Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood, 101, pp. 3118-3125.
70. Owen, C., Barnett, M. and Fitzgibbon, J. (2008) Familial myelodysplasia and acute myeloid leukaemia - a review. Br J Haematol, 140, pp. 123-132.
71. Varkonyi, J., Tarkovacs, G., Karadi, I., Andrikovics, H., Varga, F. Varga, F. et al. (2003) High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: The Budapest Study on 50 patients. Acta Haematol, 109, pp. 64-67.
72. Nearman, Z. P., Szpurka, H., Serio, B., Warshawksy, I., Theil, K. Lichtin, A. et al. (2007) Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol, 82, pp. 1076-1079.
73. Varkonyi, J., Demeter, J., Tordai, A. and Andrikovics, H. (2006) The significance of the hemochromatosis genetic variants in multiple myeloma in comparison to that of myelodysplastic syndrome. Ann Hematol, 85, pp. 869-871.
74. Greenberg, P. L. (2006) Myelodysplastic syndromes: Iron overload consequences and current chelating therapies. J Natl Compr Canc Netw, 4, pp. 91-96.
75. Malcovati, L. (2007) Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res, 31, pp. S2-S6.
76. Valent, P., Krieger, O., Stauder, R., Wimazal, F., Nosslinger, T. Sperr, W. R. et al. (2008) Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: A proposal of the Austrian MDS platform. Eur J Clin Invest, 38, pp. 143-149.
77. Hofmann, W. K., de Vos, S., Komor, M., Hoelzer, D., Wachsman, W. and Koeffler, H. P. (2002) Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood, 100, pp. 3553-3560.
78. Pellagatti, A., Esoof, N., Watkins, F., Langford, C. F., Vetrie, D. Campbell, L. J. et al. (2004) Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. Br J Haematol, 125, pp. 576-583.
79. Pellagatti, A., Fidler, C., Wainscoat, J. S. and Boultwood, J. (2005) Gene expression profiling in the myelodysplastic syndromes. Hematology, 10, pp. 281-287.
80. Paulsson, K., Heidenblad, M., Strombeck, B., Staaf, J., Jonsson, G. Borg, A. et al. (2006) High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia, 20, pp. 840-846.
81. Evers, C., Beier, M., Poelitz, A., Hildebrandt, B., Servan, K. Drechsler, M. et al. (2007) Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chromosomes Cancer, 46, pp. 1119-1128.
82. Mohamedali, A., Gaken, J., Twine, N. A., Ingram, W., Westwood, N. Lea, N. C. et al. (2007) Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood, 110, pp. 3365-3373.
83. Aivado, M., Spentzos, D., Germing, U., Alterovitz, G., Meng, X. Y. Grall, F. et al. (2007) Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci USA, 104, pp. 1307-1312.
84. Starczynowski, D. T., Vercauteren, S., Telenius, A., Sung, S., Tohyama, K. Brooks-Wilson, A. et al. (2008) High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood, 112, pp. 3412-3424.
85. Takada, S., Yamashita, Y., Berezikov, E., Hatanaka, H., Fujiwara, S. I. Kurashina, K. et al. (2008) MicroRNA expression profiles of human leukemias. Leukemia, 22, pp. 1274-1278.